According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
EIDX has been the subject of a number of other reports. BTIG Research set a $14.00 target price on ARBOR RLTY TR I/SH and gave the stock a buy rating in a report on Wednesday, April 17th. BMO Capital Markets cut Capital Power from an outperform rating to a market perform rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Eidos Therapeutics has a consensus rating of Buy and an average target price of $30.29.
Eidos Therapeutics stock opened at $39.97 on Wednesday. The firm has a 50 day moving average price of $31.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 19.04 and a current ratio of 19.04. The firm has a market cap of $1.47 billion and a PE ratio of -21.49. Eidos Therapeutics has a 12 month low of $8.89 and a 12 month high of $40.52.
Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). As a group, sell-side analysts expect that Eidos Therapeutics will post -1.73 earnings per share for the current year.
In other news, insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $23.11, for a total value of $115,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christine Siu sold 17,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $29.97, for a total value of $509,490.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,000 shares of company stock valued at $1,820,890.
Hedge funds have recently added to or reduced their stakes in the stock. Wexford Capital LP increased its holdings in Eidos Therapeutics by 100.0% during the 4th quarter. Wexford Capital LP now owns 40,000 shares of the company’s stock valued at $550,000 after purchasing an additional 20,000 shares in the last quarter. BlackRock Inc. increased its holdings in Eidos Therapeutics by 57.9% during the 4th quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after purchasing an additional 421,666 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Eidos Therapeutics during the 4th quarter valued at $1,995,000. Hillhouse Capital Advisors Ltd. acquired a new stake in Eidos Therapeutics during the 4th quarter valued at $2,458,000. Finally, Opaleye Management Inc. acquired a new stake in Eidos Therapeutics during the 4th quarter valued at $1,926,000. 34.01% of the stock is owned by hedge funds and other institutional investors.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: Why is Cost of Capital Important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.